Each drug tampers with the interplay between serotonin and dopamine, giving dopamine, carrier of lust, a temporary edge.
Thus, hypomethylation would be predicted to result in increased COMT expression, reducing tonic levels of frontal dopamine in Met carriers.
Thus, due to an increased prefrontal dopamine level, met-carriers may be able to develop a well formed and stable, spatially coded movement representation early in practice, thereby supporting the formation of a representation in motor coordinates in the course of extended practice, which later enables automatic movement execution.
In our paper we proposed various hypotheses whereby GCH1 and BH4 deficiency and consequent chronic reduction of dopamine levels may predispose carriers of GCH1 mutations to nigral cell degeneration.
In agreement with the interpretation of Terbeek et al. (2014), we believe that this case may indeed represent a case with overlapping DOPA-responsive dystonia and asymptomatic, as yet, nigrostriatal degeneration, possibly arguing against a neuroprotective role of dopamine replacement in GCH1 mutation carriers.
DRD2: Dopamine D2 receptor; SLC6A3: Solute carrier family 6, member 3 (SLC6A3); Forkheadorkhead box P2; DVD: Developmental verbal dyspraxia; CAS: Childhood apraxia of speech; SLI: Speech and language impairment; CNTNAP2: Contactin associated protein-like 2; Dyslexiasusceptibilityibilocuslocus; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium; LD: Linkage disequilibrium; OR: Odds Ratio.
It is also possible that the reduced striatal basal dopamine levels found in GCH1 mutation carriers may simply lower the threshold of nigral cell loss before parkinsonian symptoms are exhibited.
Biochemical evidence of GCH1 deficiency and reduced dopamine production has been reported in asymptomatic carriers of GCH1 mutations (Takahashi et al., 1994; Furukawa et al., 2002).
Thus, dopamine signalling is likely to be enhanced in Met carriers as compared to Val carriers.
Here, we report a dopamine conjugated nano graphene oxide (DA-nGO) carrier for cellular delivery of the anticancer drug, Methotrexate (MTX) into DA receptor positive human breast adenocarcinoma cell line.
